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Special legislation is often necessary to protect consumers
when they lack the knowledge and bargaining power to deal
effectively with the suppliers of goods.' Most consumers know
very little about medicines; upon receiving a prescription, most
people do not know what has actually been prescribed and
certainly cannot determine if they have been supplied with the
correct drug. They must trust the doctor and pharmacist to
supply the proper drug.2 Thus consumer protection legislation
is particularly necessary in the field of prescription drugs.
In recognition of this vulnerability there is much drug leg-
islation designed to protect the unknowledgeable consumer. In
1938 the Federal Food, Drug, and Cosmetic Act 3 was passed.
It protected against adulterated and misbranded5 drugs and
I See generally S. MoRGAsTRN, LEGAL PROTECrION FOR THE CONSUMER (2d ed.
1978).
2 When the consumer reposes a high level of trust and confidence in the
expertise of a provider of goods or services, the law commonly treats this
vendor in a fashion different from the manner in which it treats other sup-
pliers of goods and services. Accordingly, the law regulates the professions
to a greater extent than other occupations. This scrutiny stems largely from
the inability of the public to protect itself adequately in a situation where
its members engage the professional on the understanding that he will put
their interests before his own. Because the professional is deemed to be a
fiduciary, the rule of caveat emptor does not apply. This is clearly the case
with the professional pharmacist. He stands as a fiduciary for most transac-
tions, and particularly in the case of prescription drugs, the public must trust
the ability of the pharmacist to dispense properly those commodities on
which health and life depend.
Willig, The Prosubstitution Trend in Modem Pharmacy Law, 6 U. MICH. J.L. REF. 1
(1972).
3 21 U.S.C. §§ 301-92 (1976). This Act replaced the Federal Food and Drugs Act
of 1906. 21 U.S.C. §§ 1-5, 7-15 (1976).
21 U.S.C. § 351 (1976).
21 U.S.C. § 352 (1976).
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provided, among other things, performance standards for es-
tablished' and new7 drugs. Most states, in turn, adopted at
least some type of pure food and drug legislation.' In addition,
every state, in an effort to ensure competence and high stan-
dards, has statutes regulating the pharmacies and pharmacists
who dispense the drugs.'
21 U.S.C. § 360(d) (1976).
21 U.S.C. § 355 (1976).
See ALA. CODE tit. 20, 1-1 to -137 (1975); ALASKA STAT. §§ 17.05.010 - .20.380
(1962); ARK. STAT. ANN. §§ 82-1101 to -1123 (1947); CAL. HEALTH & SAFETY CODE §§
26001 - 26693 (West 1967 and Supp. 1978); COLO. REv. STAT. §§ 25-5-401 to -5-425
(1973); CoNN. GEN. STAT. §§ 19-211 to -243 (1975); DEL. CODE ANN. tit. 16 §§ 3301 -
3322 (1974); D.C. CODE ANN. §§ 33-101 to -112 (1973); FLA. STAT. ANN. § 859.08 (West
1976); GA. CODE ANN. §§ 79A-1001 to -1018 (1973); HAWAn REV. STAT. §§ 328-1 to -29
(1976); IDAHO CODE §§ 37-113 to -134 (1977); ILL. ANN. STAT. ch. 56 12, §§ 501 - 526
(Smith-Hurd Supp. 1978); IND. CODE ANN. §§ 16-1-28-1 to-1-28-39 (Burns 1973); IOWA
CODE ANN. §§ 203A.1 - .19 (West 1969); KAN. STAT. §§ 65-655 to -680 (1972); Ky. REv.
STAT. §§ 217.005 - .215 (1977) [hereinafter cited as KRS]; LA. REv. STAT. ANN. §§
40:601 - :1059 (West 1974); ME. REv. STAT. tit. 7, §§ 481 - 489 (1964); MD. ANN. CODE
art. 43, §§ 187 - 197 (1957); MASS. ANN. LAWS ch. 94, §§ 186 - 196 (Michie/Law. Co-
op. 1975); MICH. CoMP. LAws ANN. § 338.1124 (1976); MINN. STAT. ANN. §§ 151.34 -
.36 (West 1970); Miss. CODE ANN. §§ 75-29-1 to -29-29 (1972); Mo. ANN. STAT. §§
196.010 - .180 (Vernon 1973); MONT. Rzv. CODES ANN. § 66-1524 (1947); NEB. REv. STAT.
§§ 71-2401 to -2405 (1943); NEv. REv. STAT. §§ 585.010 - .550 (1973); N.H. REV. STAT.
ANN. §§ 146:1 - :21 (1964); N.J. STAT. ANN. §§ 24:5-1 to :5-22 (West 1940); N.M. STAT.
ANN. §§ 54-6-1 to -6-19 (1953); N.Y. EDUC. LAW § 6815 (McKinney 1972 and Supp.
1978); N.C. GEN. STAT. §§ 106-120 to -145 (1978); N.D. CENT. CODE §§ 19-02.1-01 to -
02.1-24 (1960 and Supp. 1978); OHIO REv. CODE ANN. §§ 3715.01 -.99 (Page 1971); OKLA.
STAT. ANN. tit. 63, §§ 1-1408 and -1409 (West 1973); R.I. GEN. LAws §§ 21-31-1 to -31-
23 (1956); S.C. CODE §§ 39-23-10 to -23-130 (1976); S.D. CODIFIED LAws §§ 39-15-1 to -
15-11 (1977); TENN. CODE ANN. §§ 52-101 to -124 (1977); Tax. REv. CiVm STAT ANN. §
4476-5 (Vernon 1976); UTAH CODE ANN. §§ 4-26-1 to -26-26 (1953); VT. STAT. ANN. tit.
18, § 4064a (Supp. 1978); VA. CODE §§ 54-524.85 to -524.100 (1950); WASH. REV. CODE
§§ 69.04.001 - .04.930 (1976); W. VA. CODE §§ 16-7-1 to -7-11 (1972); Wyo. STAT. §§
35-222 to -262 (1957).
See ALA. CODE tit. 34, §§ 23-1 to -94 (1975); ALAsKA STAT. §§ 08.80.010 - .80.490
(1962); Amiz. REv. STAT. ANN. §§ 32-1901 to -1996 (1976); ARK. STAT. ANN. §§ 72-1001
to -1061 (1947 and Supp. 1977); CAL. Bus. & PROF. CODE §§ 4000 - 4416 (West 1974);
COLO. REv. STAT. §§ 12-22-101 to -22-415 (1973); CONN. GEN. STAT. §§ 20-163 to -185
(1975); DEL. CODE ANN. tit. 24, §§ 2501 - 2591 (1974); D.C. CODE ANN. §§ 2-601 to -617
(1973); FLA. STAT. ANN. §§ 465.011 - .31 (West 1965 and Supp. 1978); GA. CODE ANN.
§§ 79A-101 to -9917 (1973); HAWAII REV. STAT. §§ 328-1 to -29 (1976); IDAHO CODE §§
A54-1701 to C54-1738 (Supp. 1978); ILL. ANN. STAT. ch. 91, §§ 55.1 - .63 (Smith-Hurd
1966); IND. CODE ANN. §§ 25-26-13-1 to -26-13 -29 (Bums Supp. 1978); IOWA CODE ANN.
§§ 155.1 - .35 (West 1972); KAN. STAT. §§ 65-1625 to -1652 (Supp. 1978); KRS §§
315.010 - .991 (1977); LA. REv. STAT. ANN. §§ 37:1171 - :1208 (West 1974 and Supp.
1978); ME. REv. STAT. tit. 32, §§ 2801 - 2914 (1964); MD. ANN. CODE art. 43, §§ 249 -
273B (1957 and Supp. 1978); MAss. ANN. LAWS ch. 112, §§ 24 - 42A (Michie/Law. Co-
op 1965); MIcH. COMP. LAWS ANN. §§ 338.1101 - .1130 (1976); MINN. STAT. ANN. §§
151.01 - .40 (West 1970); Miss. CODE ANN. §§ 73-21-1 to -21-65 (1972); Mo. ANN. STAT.
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§§ 338.010 - .310 (Vernon 1966 and Supp. 1979); MONT. REv. CODES ANN. §§ 66-1501
to -1536 (1947 and Supp. 1977); NaB. REv. STAT. §§ 71-1142 to -1147.16 (1943); NEV.
REv. STAT. §§ 639.001 .310 (1977); N.H. REv. STAT. ANN. §§ 318:1 - :55 (1966); N.J.
STAT. ANN. §§ 45:14-1 to :14-39 (West 1978); N.M. STAT. ANN. §§ 67-9-33 to -9-59
(1974); N.Y. EDUc. LAW §§ 6800 - 6826 (McKinney 1972 and Supp. 1978); N.C. GEN.
STAT. §§ 90-53 to -85.1 (1975); N.D. CENT. CODE §§ 43-15-01 to -15-45 (1978); OHIo REv.
CODE ANN. §§ 4729.01 - .99 (Page 1977); OKLA. STAT. ANN. tit. 59, §§ 353.1 - .27 (West
1973); OR. REv. STAT. §§ 689.010 - .990 (1977); PA. STAT. ANN. tit. 63, §§ 390-1 to -13
(Purdon 1968); R.I. GEN. LAws §§ 5-19-1 to -19-37 (1976); S.C. CODE §§ 40-43-10 to -
43-470 (1976); S.D. CODIFIED LAWS §§ 36-11-1 to -11-66 (1977); TENN. CODE ANN. §§
63-1001 to -1025 (1976); TEx. Rav. Civ. STAT. ANN. § 4542a (Vernon 1976); UTAH CODE
ANN. §§ 58-17-1 to -17-28 (1953); VT. STAT. ANN. tit. 26, §§ 1891- 2016 (1975); VA. CODE
§§ 54-524.1 to -524.78 (1950); WASH. REV. CODE §§ 18.64.001 -.64.920 (1976); W. VA.
CODE §§ 30-5-1 to -5-24 (1976); Wis. STAT. ANN. §§ 450.01 - .13 (West 1974); WYo. STAT.
§§ 33-304.1 to -304.46 (Supp. 1975).
Pharmacy laws generally provide for:
1. The educational and experience qualifications which pharmacists
must meet at the time of examination or registration.
2. The agency, usually known as the State Board of Pharmacy,
charged with the enforcement and administration of the law.
3. "The granting of permits for the conduct of a community pharmacy
or drug store. In most states permits are issued for one year and application
must be made for their renewal.
4. The minimum of professional and technical equipment and appara-
tus which the pharmacy must, at all times, possess. The [United States
Pharmacopeial and the [National Formulary] are generally included in
this requirement.
5. Periodic re-registration of pharmacists. In most states certificates of
registration are granted for the period of one year.
6. The conditions under which certificates of registration or store per-
mits may be canceled or revoked.
7. The prominent display of the certificates of registration in the store
or pharmacy in which the holder is employed.
8. Penalities for violations. Infractions of pharmacy laws are punisha-
ble by fines in most instances.
9. Reciprocal registration. A pharmacist licensed by examination in
one state may, by conforming to more or less nominal rules, become regis-
tered in another state, the latter registration being without examination.
10. The discretion vested in boards of pharmacy. While the Board is
authorized to make rules and regulations for the enforcement and adminis-
tration of the pharmacy law, such rules and regulations must be strictly in
accord with the expressed or implied purposes of the law. The Board is an
administrative, not legislative, agency. It may not exercise any power or
authority not clearly delegated to it, or which by reasonable implication is
necessary to the proper functioning of the pharmacy law.
11. The sale of proprietary and patent medicines, and commonly used
household and domestic remedies by dealers other than pharmacists. As a
rule, such dealers are unrestricted in the sale of preparations falling in these
classifications, although in some states permits by the Board of Pharmacy
are required.
REMINGTON'S PHARMACEUTICAL SCIacES 1841-42 (15th ed. 1975).
[Vol. 67
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These measures have provided protection for the consumer
as to quality, yet they have failed to protect the consumer as
to value. Drugs received may be of high quality but are they
actually worth the high price the consumer is paying? The
consumer can do very little about prescription drug prices.0
Physicians prescribe certain drugs, often by brand name, and,
in many states, the pharmacist must supply that brand of
drug." Even if permitted to substitute, many pharmacists do
not substitute lower .priced drugs. Under these conditions, con-
sumers could save money on drugs only by comparison shop-
ping at various pharmacies. Such a practice is not only im-
practical since prescription drugs are not accessible to shop-
pers, but it would probably result in only a small savings.
To provide the consumer with some protection as to the
value of drugs purchased, many states have enacted generic
drug substitution laws. In fact, legislation of this type has
mushroomed in recent years. 2 This Note will examine the na-
ture of generic drugs and the types of laws that have been
enacted to encourage their use. Attention will be focused on the
structure of these laws and some of the problems with them.
Finally, other means of protecting the consumer in the field of
prescription drugs will be evaluated.
The drug industry has been found to have an exceptionally high profit ratio. THE
DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE, FINAL REPORT OF THE TASK FORCE
ON PRESCRIPTION DRUGS, xi (1969).
Adding to the problem of high price is the fact that only a small number of firms
produce prescription drugs. Approximately 95% of all the drugs sold in the United
States come from 136 manufacturers and over 60% of the 500 largest selling drugs are
produced by only 24 firms. Green, Welfare Losses From Monopoly in the Drug Indus-
try: The Oklahoma 'Antisubstitution Law, 5 ANTITRUST L. & ECON. REv., No. 3, 97,
100 (1972).
t It is for this reason that drug manufacturers have traditionally aimed their
advertising at physicians rather than the actual consumer. Willig, supra note 2, at 16.
12 As one commentator put it:
I am convinced that consumer protection is not a passing fad; it has been
our chief concern in the food and drug field for many years and will continue
to be so. As we move into the 70's, and as the voice of the consumer is heard
more and more throughout the land, it is the obligation of all of us to harken
'to that voice. It is the obligation of all of us to work to preserve and protect
the consumer by giving him a better and more informed choice in a market-
place of safer, more effective, better quality and less hazardous products.
Epstein, Food and Drug Law and Consumer Protection in the Seventies, 27 FOOD,
DRUG, CoNsM. L. J. 376, 382 (1972).
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I. GENERIC DRUGS
Any particular drug ordinarily has three names by which
it is identified. The first is the chemical name which describes
the structure of the drug in chemical terms. The second is the
nonproprietary or generic name which indicates the chemical
class to which the drug belongs. Finally, there is the trademark
or brand name which is a registered name of the manufac-
turer.'3 Drugs are like most other consumer goods in that the
same generic drug is often made by several different manufac-
turers and simply given their respective brand names." As with
other goods, drugs sold under a brand name generally cost more
than those sold under the generic names.'5 In addition, there
are often large price differences between various brands of the
same drug and between brand name and generic varieties of
the same drug."6 The generic drug substitution laws are de-
* REMINGTON'S PHARMACEUTICAL SCIENCES 1309 (15th ed. 1975). For example, the
names of one drug are: "Aspirin," the nonproprietary or generic name; "acetylsalicylic
acid," the chemical name; and "Bayer," the trademark or brand name.
Thus, the term "generic" refers to "a class of chemical substances having the same
biological properties." Feldmann, Brand Versus Generic Drugs, 9 J. AM. PHARM. A. 8
(1969). Drugs sold under a generic and not a brand name are referred to as "generic
drugs" or "generics."
" For example, in the grocery line canned corn (generic name) is manufactured
by several different companies under such names as Green Giant and Libby's, but the
basic product is still the same. In the drug line the drug ampicillin (generic name) is
manufactured by several different companies under such names as Amcill, Omnipen,
Pen A, and Polycillin (brand names).
'1 Prices of brand name drugs can be more than three times greater than those of
their generically sold counterparts. Note, Improving Michigan's Generic Drug Law, 9
U. MICH. J. L. REF. 394, 395 (1976).
,1 A sample of the average wholesale prices of various brands and the generic form
of the drug Ampicillin are set out below.
AMPICILLIN (250 ,mg. capsule form)
Brand Distributor Price per 100
Alpen Lederle $ 8.61
Amcill Parke-Davis 11.27
Amperil Geneva Drugs, Ltd. 4.99*
Omnipen Wyeth Labs 11.25





SK-Ampicillin** Smith, Kline & French 7.25
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signed to allow the consumer to take advantage of these differ-
ences in prices of the same drug. To understand how these new
laws operate it is first necessary to understand laws which pre-
vent the consumer from taking advantage of these differences
in drug prices.
A. The Antisubstitution Laws
Originally, a substitution referred to the use of a drug with
a different generic or chemical makeup than the one pre-
scribed. It was widely accepted that such substitution was dan-
gerous and should be prohibited. However, substitution has
come to mean "[a]ny act resulting in a variation between the
prescription pharmaceutical requested and that pharmaceuti-
cal dispensed."17 In the early 1950's the drug industry began
pushing for antisubstitution laws that would include a prohibi-
tion against the substitution of one brand of drug for another.18
The American Pharmaceutical Association joined in support-
ing these laws,1 and by 1972 forty-seven states had laws mak-
ing it illegal to substitute even a chemically equivalent 0 drug
Supen Reid-Provident Labs 11.95
Totacillin Beecham Labs 13.75
Vampen Vanguard Labs 8.00
Generic
Ampicillin Bocan Drug Co. 6.75
Ampicillin Trihydrate Bell Pharmacal 6.46
Paramount Surgical Supply 5.25
Pure-Pac Pharmaceutical 6.81
Zenith Labs 6.00
*only available in 500 **Manufactured by Bristol
Prices are from DRUG Topics RED BOOK (1978). All of these brands were found to be
therapeutically equivalent by the Kentucky Drug Formulary Council. 902 Ky. AD.
RGs. 1:020 (1978). See notes 32-40 and accompanying text infra for an explanation of
therapeutic equivalency.
11 Willig, supra note 2, at 2. The substitution of one drug for another is not a recent
problem; the practice dates from the 8th century B.C. Id., at n.3.
z Green, supra note 10, at 108.
"Feldmann, The Brand Name System - An Intrusion Upon the Profession, 11 J.
AM. PHARM. A. 376, 376 (1971). The American Pharmaceutical Association purportedly
supported these laws in an effort to combat the counterfeit drug problem that emerged
after World War II. Id.
" Chemical equivalents are defined as "[dirug products that contain the same
amounts of the same therapeutically active ingredients in the same dosage forms and
that meet present compendial standards." OFFICE OF TECHNOLOGY AssEssMErN, DRUG
BIOEQUIVALENCE STUDY PANEL, DRUG BIOEQUIVALENcE, vi (1974) [hereinafter cited as
1978-79]
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for the particular brand narded in the prescription."
As a result, the drug companies aimed advertising cam-
paigns directly at doctors in the hope that once doctors became
familiar with a brand name it would become a habit to write
all future prescriptions for that drug by brand, rather than
generic, name." As long as the prescription was written for a
particular brand no other brand or even the generic form could
be used to fill that prescription. However, if a doctor wrote the
prescription using the generic name of the drug, then any com-
pany's product could be used. The campaigns were very suc-
cessful for the drug companies and by 1972 approximately
ninety percent of all prescriptions were written for the brand
name drugs."
The cost of this advertising by brand name manufacturers
was, of course, reflected in the increased cost of their drugs.24
It is for this reason that the use of generic drugs became attrac-
tive as a means of reducing drug prices. The first attempt to
make use of generic prescribing resulted in the 1962 Amend-
ments to the Federal Food, Drug, and Cosmetic Act.21 These
amendments sought, among other things, to reduce drug prices
by encouraging physicians to prescribe by generic rather than
DRUG BIOEQUIVALENCE]. The present compendial standards refer to standards for drug
products listed in the United States Pharmacopeia and the National Formulary. Id.
2, See Green, supra note 10, at 108. For example, one antisubstitution law reads
as folllows:
The intentional act of substituting or otherwise changing the content,
formula or brand of any drug prescribed by written or oral prescription
without prior Written or oral approval from the prescriber for the respective
change in each prescription [is unprofessional conduct for which the phar-
macist's license can be revoked].
Mo. ANN. STAT. § 338.055 (5) (Vernon Supp. 1979).
2 The drug companies were aided in their campaign by the fact that for the 17-
year life of the patent on any new drug only the patentholder's brand was available
and the physicians would become accustomed to only writing prescriptions for that
brand. Whenthe patent expired other companies started making and selling the drug
under its generic name but the doctor's habit of writing prescriptions for the brand
name was hard to break. Another incentive to prescribe by brand name is the fact that
brand names are often simpler than generic names. For example, the brand name
"Dexedrine" is much easier to write than the generic name of "dextroamphetamine
sulfate."
23 See Note, Products Liability for Prescription Drugs-The Effects of Generic
Substitution on the Consumer and the Pharmacist, 23 SYR. L. REv. 887, 888 (1972).
z1 It has been estimated that large drug manufacturers' advertising expense
amounts to 24% of every sales dollar. Willig, supra note 2, at 16.
Drug Amendments of 1962, 76 STAT. 780 (1962), 21 U.S.C. §§ 301-92 (1976).
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brand name. 6 A movement then began to repeal the antisub-
stitution laws and allow the pharmacist to exercise professional
expertise in selecting which manufacturer's product to use, re-
gardless of which brand the prescription named. This was the
beginning of the generic drug substitution laws in the early
1970's. However, a problem arose in connection with antisub-
stitution laws: Even though generic drugs might be more eco-
nomical, are generic drugs really equivalent to their brand
name counterparts?
B. The Problem of Equivalence
Consumers often hesitate to buy a cheaper, non-brand
name product for fear that the lower price is due to poorer
quality. This fear is the basis for some of the opposition to
substitution with generic drugs. Many people feel that the gen-
erally smaller firms that manufacture generic drugs do not pro-
vide for the quality controls of the larger brand name manufac-
turers, and may not follow good manufacturing practices re-
quired by the official compendia.2" A study on drug product
safety concluded: "Drug products from different sources may
differ in quality in several respects. These differences, individ-
ually or collectively, may lead to substantial differences in
therapeutic effect and/or safety." 8 While this does not prove
2' See Note, Drug Amendments of 1962-Generic-Name Prescribing: Drug Price
Panacea?, 16 STA. L. REv. 649, 653-55 (1964).
Generic name prescribing was encouraged by assuring physicians that all drugs
manufactured in the United States met a specified standard of quality whether they
were made by a large brand name manufacturer or a small generic name manufacturer.
Also, generic names were brought to the attention of physicians by requiring that all
advertising carry the generic as well as any brand name. Id.
Physicians did increase the number of generic prescriptions they wrote from 6.4%
of all new prescriptions in 1966 to 10.6% in 1973. Myers and Fink, Liability Aspects of
Drug Product Selection, 17 J. AM. PHiA. A. 33, 33 (1977). In addition, a survey of
Michigan physicians found that 61% of the physicians surveyed said they write their
prescriptions generically sometimes or as often as possible. Goldberg, et. al., Evalua-
tion of Impact of Drug Substitution Legislation, 16 J. AM. PHAaM. A. 64, 90 (1976).
21 See Note, supra note 23, at 889-97.
Two groups of drug manufacturers have been identified: (1) The brand name firms
which provide full service and do their own research and development, and (2) the
"marginal" operators who do not do their own research but simply imitate previously
marketed drugs. See Feldmann, supra note 19, at 377. A compendium is an official
source of information regarding strength, quality, purity, packaging and labeling of
drugs.
AMERICAN PHARmAcEuTIcAL AssocIATIoN ACADEMY OF PHARMACEUTICAL SCIENCES,
Drug Product Quality, 10 J. AM. PHARM. A. 107, 116 (1970). In addition, it is feared
1978-79]
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that generic drugs are of a lesser quality than brand names, it
does illustrate that there are differences in manufacturing
which affect the usefulness of the drug. Supporters of generic
drug substitution have pointed out that the size of a company
does not necessarily indicate the quality of its products.29 Sena-
tor Gaylord Nelson pointed out that "some of the best-known
drug companies have violated-some repeatedly-the good
manufacturing practices (GMP) provisions of the law."31 No
widespread difference between the products of large brand
name manufacturers and small generic name manufacturers
has been documented. 31
While the debate over the relative quality of generic drugs
continued, a more serious problem in the movement toward
substitution was recognized in the early 1970's: bioequiva-
lency.32 It was discovered that "some drugs may be 'generically
that the smaller manufacturers may have so few assets as to be substantially judgment
proof from any liability they may incur on account of their drugs.
It has been suggested that pharmacists may oppose generic drug substitution on
the ground that they may incur liability in making such substitutions. See Note, supra
note 23, at 897.
" Feldmann, supra note 19, at 379. For example, one of the largest drug manufac-
turers in the United States was criticized by a Senate subcommittee for its "extremely
poor manufacturing practices that resulted in numerous mixups, recalls, adulterated
and misbranded products." Id.
11 Big Boost For Generic Drugs, DRUG TOPICS 14 (Dec. 15, 1977). However, the
president of the Pharmaceutical Manufacturers Association stated that quality may
vary depending on manufacturing know-how. Id.
11 Donald Kennedy, a Food and Drug Administration commissioner, has been
quoted as saying that there is no evidence of widespread differences between the
products of large and small firms, or between brand-name and generic-name products.
Big Boost For Generic Drugs, DRUG ToPiCS 18 (Dec. 15, 1977).
2 In order to understand the bioequivalency problem, some basic definitions are
necessary.
Two drugs are chemically equivalent when they contain the same amount of the
same active ingredients. As explained in note 20 and accompanying text supra generic
and brand name drugs are chemically equivalent.
The bioavailability of a drug refers to a measurement of the rate and extent to
which an administered drug reaches general circulation in the blood stream. This is
often indicated by means of a graph showing the serum level of the drug over a period
of time.
Two chemically equivalent drugs are also bioequivalent if when administered in
the same amount to the same individual they result in essentially the same bioavaila-
bility.
Finally, two chemically equivalent drugs are therapeutically equivalent if when
administered in the same amount to the same individual they result in essentially the
same therapeutic response. See DRUG BIOEQUIVALENCE, supra note 20, at vi;
REMINGTON'S PHARMACEUTICAL SCIENCES 1368 (15th ed. 1975).
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equivalent' but 'therapeutically nonequivalent.' 3 That is, two
drugs that have the same chemical ingredients may not have
the same effectiveness in treating a disease or condition. Most
drug products are mixtures of active and inert ingredients that
go through a complicated manufacturing process before reach-
ing the form in which they are sold. Even small differences in
this manufacturing process may result in differences in the
therapeutic efficacy of the final drug products. For example,
two drugs may have the same active chemical ingredients but,
because of differences in the inert ingredients or manufacturing
techniques, have different dissolution rates. Thus, one of the
drugs would dissolve and start working before the other. In
situations where the speed of a drug is important, differences
in the dissolution rate could be critical. Therefore, the faster
acting drug would be more therapeutically effective.
The difference in therapeutic efficacy usually corresponds
with a difference in the bioavailability34 of the two drugs. Dif-
ferences in bioequivalency can result even though the manufac-
turers have complied with good manufacturing practices. Two
drugs can meet all the standards in the official compendia and
still vary in bioavailability.35 As a government study on drug
bioequivalency concluded:
Current standards and regulatory practices do not insure
bioequivalency for drug products.
Since the studies in which the lack of bioequivalency was
demonstrated involved marketed products that met current
compendial standards, these documented instances consti-
tute unequivocal evidence that neither the present standards
for testing the finished product not the specifications for ma-
terials, manufacturing processes, and controls are adequate
REMINGTON'S PHARMACEUTICAL SCIENCES 1309 (15th ed. 1975).
" For an explanation of bioavailability see note 32 supra.
The reason why these generic products exhibit varying blood levels
[bioavailability] is a result of complex manufacturing techniques required
to put the raw drug in a final dosage form. Most drugs are not administered
in the form of a simple drug entity, but more often as complex mixtures of
the drug with various other ingredients required to make a precise, effective,
stable, and convenient dosage form. There are as many as thirty-two differ-
ent factors which can affect the efficacy of a drug.
Note, supra note 23, at 892 (footnotes omitted). See also REMINGTON'S PHARMACEUTICAL
SCIENCES 1309 (15th ed. 1975).
1978-79]
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to insure that ostensibly equivalent drug products are, in
fact, equivalent in bioavailability.
Present compendial standards and guidelines for Cur-
rent Good Manufacturing Practices do not insure quality and
uniform bioavailability for drug products. Not only may the
products of different manufacturers vary, but the product of
a single manufacturer may vary from batch to batch or may
change during storage."
The problem is, again, not just the quality of drugs, but also
the therapeutic inequivalency of the same drug produced by
many different manufacturers, or, indeed, the same drug as
made by one manufacturer at different times.
This makes substitution harder because it is very difficult
to determine when two drugs are therapeutically equivalent.
Therapeutic equivalency can only be conclusively determined
from clinical tests which measure how a person reacts to cer-
tain drugs. Such tests are practically impossible to conduct
accurately. Therefore, the general practice is that bioequival-
ance tests are conducted and it is assumed that if two drugs
are biologically equivalent then they are therapeutically equiv-
alent." However, such an assumption is not necessarily correct.
"The critical relationship between bioavailability measure-
ments and therapeutic efficacy is in most cases still ambigu-
ous."3 Even if the correlation between bioequivalency and
therapeutic efficacy is accepted, there is still no general source
of bioavailability data on every drug. Bioavailability tests are
not included in the compendia because pharmaceutical scien-
tists can not agree on the standards." It is possible to seek
bioavailability data from the manufacturer of the drug, but
most manufacturers' tests differ so that comparison of results
for different products is almost impossible. 0 Given the increas-
11 DRUG BIOEQUIVALENCE, supra note 20, at 11, 12, 25.
31 REMINGTON'S PHARMACEUTICAL SCIENCES 1310 (15th ed. 1975). "Thus, if two prep-
arations are generally equivalent and yield similar blood absorption and urinary excre-
tion curves for the active ingredient after administration, they are assumed to be
therapeutically equivalent and to elicit similar pharmacologic effects." Id.
Benet, The American Pharmaceutical Association Bioavailability Project: A
Wrap-Up, 17 J. AM. PHARM. A. 753, 754 (1977).
' Feldmann, supra note 13, at 12.
Individual practitioners had often requested bioavailability data from
manufacturers, only to find that the information provided raised more ques-
tions than it answered. Few studies were parallel in any way; each involved
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ing recognition of the importance of bioequivalency of drug
products, much more testing and research is needed.
This, then, was the major problem faced by those who
wanted to repeal the antisubstitution laws. If substitution is
allowed, how can the pharmacist and consumer be assured that
the substituted drug is truly equivalent to the drug originally
prescribed?" Generic drug laws had to incorporate consumer
protection against non-equivalent drugs as well as protection
against high prices. Yet, generic drug laws could not be ex-
pected to solve the therapeutic equivalency problem since equi-
valency is a problem even for brand name drug products.42
II. THE GENERIC DRUG SUBSTITUTION LAWS
A. In General
Between 1972 and 1979 thirty-one states and the District
of Columbia 3 abandoned their antisubstitution laws and en-
different designs, different dosage forms, different means of reporting and
analyzing statistics, and so made exact comparison of products exceedingly
difficult, if not impossible.
Editorial, Bioavailability Wrap-Up, 17 J. AM. PHwRM. A. 729, 729 (1977).
11 Although it has been suggested that the actual number of nonequivalent drugs
is low, the potential danger from nonequivalency is considered important enough to
warrant major concern. See generally DRuG BIoEquQvAxNcE, supra note 20, at 14;
REMINGTON'S PHARMACEUTICAL SCIENCES 1309 (15th ed. 1975); Willig, supra note 2, at
16.
,2 Nonequivalent drug products may also be a concern even if substitution is not
permitted since a drug from a brand-name manufacturer may differ in bioavailability
from batch to batch. However, since an individual manufacturer probably uses the
same manufacturing process for each batch of a drug, the danger of differences in
bioavailability is less than when two different manufacturers are producing the same
drug product. For this reason the bioequivalence problem has acquired particular
significance where generic drug laws permit substitution with a drug product of a
different manufacturer. Nevertheless, a need for comprehensive and continuing bioa-
vailability studies of all drug products is indicated.
13 See ALASKA STAT. § 08.80.295 (Supp. 1978); ARiz. REv. STAT. ANN. § 32-1963.01
(Supp. 1978); ARK. STAT. ANN. §§ 72-1047 to -1048 (Supp. 1977); CAL. Bus. & PROF.
CODE § 4047.6 (West Supp. 1978); COLO. REv. STAT. § 12-22-118.5 (Supp. 1976); DEL.
CODE ANN. tit. 24, § 2589 (Supp. 1978); D.C. CODE ANN. § 33-832 (Supp. 1978); FLA.
STAT. ANN. § 465.30 (West Supp. 1978); GA. CODE ANN. § 79A-408.2 (Supp. 1978); IOWA
CODE ANN. § 155.37 (West Supp. 1978); KRS § 217.822 (1977); ME. REv. STAT. tit. 32,
§ 2806 (Supp. 1978); MD. ANN. CODE art. 43, § 273A (Supp. 1978); MICH. CoMp. LAWS
ANN. § 338.1114a (Supp. 1978); Mo. ANN. STAT. § 338.056 (Vernon Supp. 1979); MONT.
REv. CODES ANN. § 66-1528 to -1536 (Supp. 1977); NEB. REv. STAT. §§ 71-5401 to -
5408 (Supp. 1978); N.J. STAT. ANN. § 24:6E-7 and 8 (West Supp. 1978); N.Y. EDuc.
LAW § 6816-a (McKinney Supp. 1978); Omo REv. CODE ANN. § 4729.38 (Page Supp.
1978); Oa. REv. STAT. § 689.830 - .850 (1977); PA. STAT. ANN. tit. 35, §§ 960.2 - .7
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acted various types of laws permitting substitution. Although
these laws have many common characteristics, there are signif-
icant differences among them. Two characteristics serve to dis-
tinguish "generic drug"" laws: the degree of permissiveness in
making substitution and the method of designating which
drugs are equivalent for substitution purposes (the formu-
lary).45
1. The Degree of Permissiveness in Substituting
Basically there are two types of generic drug laws-
permissive and mandatory." While this may appear to be a
fairly clear cut distinction, the various state statutes actually
form a continuum between these two extremes. No state pro-
vision is totally mandatory, but the states that are closest to
the mandatory pole are Kentucky,47 Florida," Rhode Island,"
Vermont," and Wisconsin." The statutes in these states pro-
vide that a pharmacist shall substitute a lower price equiva-
lent drug. While this seems like a mandate that the consumer
shall always receive the lowest cost equivalent drug available
(Purdon 1977); R.I. GEN. LAWS §5-19-38 (Supp. 1978); S.C. CODE § R99-22 (1976); S.D.
CODIFIED LAWS §§ 36-11-46.1 to -11-46.4 (Supp. 1978); TENN. CODE ANN. §§ 52-1221 to
-1226 (Supp. 1978);UTAH CODE ANN. §§ 58-17-29 to -17-35 (Supp. 1977); VT. STAT. ANN.
tit. 18, § 4605 (Supp. 1978); VA. CODE § 54-524.109:17 (1978); WASH. REV. CODE §§
69.41.100 - .41.180 (Supp. 1977); W. VA. CODE § 30-5-12b (Supp. 1978); Wis. STAT. ANN.
§ 450.075 (West Supp. 1978).
" These laws appear to have acquired the popular name of "generic drug laws"
even though a more technically correct name may be "drug substitution laws."
1 The formulary system is a process whereby a group of drug experts determines
which drugs may be safely used as substitutes for a particular drug. Thereafter any
prescription for that particular drug may be filled with any one of the drugs on the
formulary list of substitutes. This formulary system is a means of getting around the
problem of nonequivalence.
The formulary system is also often used in large hospitals where prescription forms
bear legends consenting to substitution and a committee of physicians, administrators
and pharmacists determine what drugs will be on the hospital formulary. Willig, supra
note 2, at 6.
"' Permissive laws allow pharmacists to substitute but do not require them to do
so. Mandatory laws require pharmacists to substitute and thereby deny them any
choice.
" KRS § 217.822 (1977). For a more detailed discussion of the Kentucky law see
notes 115-30 and accompanying text, infra.
" FLA. STAT. ANN. § 465.30 (West Supp. 1978).
" R.I. GEN. LAWS § 5-19-38 (Supp. 1978).
VT. STAT. ANN. tit. 18, § 4605 (Supp. 1978).
Wis. STAT. ANN. § 450.075 (West Supp. 1978).
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whenever having a prescription filled, that result does not al-
ways follow. Two of these statutes-Kentucky's and Flor-
ida's-appear to have loopholes. These statutes require substi-
tution of lower price drugs only if the original prescription is
written for a brand name drug. 2 Thus, if the original prescrip-
tion is written by generic name the pharmacist may fill it with
any manufacturer's form of that drug,53 not necessarily the
drug with the lowest cost.5" While the importance of this loop:
hole may be slight given the small number of prescriptions
that are written generically,5 it nevertheless represents a temp-
tation to unscrupulous druggists that could easily have been
avoided.56 Actually this temptation to use a higher price generic
may be small given the competition between pharmacies. How-
ever, the states with more mandatory provisions appear to have
taken the position that competition is not sufficient to ensure
the use of lower cost drugs. If this is their position then they
should require the use of the lowest cost equivalent when the
prescription is written for the generic name drug as well as
when it is written for the brand name. Wisconsin avoids this
problem in part by simply stating that every prescription shall
be filled with a lower than average cost equivalent.57 Vermont
provides the most benefit for the consumer by providing that
if the prescription is by either the generic or brand name the
pharmacist shall select the lowest priced equivalent drug.58 Al-
though the statutes of these states are the closest to mandating
substitution, they all provide an exception when the prescriber
specifies that no substitution should be made." In addition, the
12 See FLA. STAT. ANN. § 465.30 (2) (West Supp. 1978); KRS § 217.822 (1) (1977).
53 "Where the physician writes the prescription using only the generic designation,
the pharmacist is permitted to select any company's product." Note, supra note 23,
at 888.
5' The price difference may be significant even among the generic manufacturers.
See note 16 supra for an example of the variation.
Approximately 10% of new prescriptions are written generically, but the number
is increasing. See How Pharmacists' Generic Preferences Have Changed, 172 Am.
DRUGGIST 23 (1975).
11 It is ironic that a physician who writes a prescription for a drug by its generic
name may end up costing the consumer more than if it had been written for a brand
name.
9 See Wis. STAT. ANN. § 450.075(2) (West Supp. 1978). Note that this statute only
requires a lower than average cost, not the lowest.
' See VT. STAT. ANN. tit. 18, § 4605(a) (Supp. 1978).
5' See FLA. STAT. ANN. § 465.30(2) (West Supp. 1978); KRS § 217.822 (2) (1977);
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consumer may request that substitution not be made. 0
The next group of statutes along this mandatory-
permissive continuum also requires that substitution of a less
expensive drug shall take place unless the prescribing physi-
cian indicates otherwise. This type of statute works very much
like the first group in that unless substitution is expressly pro-
hibited by the physician, it is required-the pharmacist has no
choice. Yet, these statutes' are different in that they force the
physician to either consent to substitution or specify that it
should not take place. All prescription forms are required to
have two signature lines-one indicating that substitution is
required and the other indicating that substitution is not al-
lowed.12 Whenever physicians write a prescription they must
make a choice in signing the prescription as to whether substi-
tution is required. Apparently the purpose of the two signature
lines is to make the prescriber consciously consider whether
substitution should be permitted in that particular case. The
danger with this is that a physician may sign one line or the
other out of habit.
The next type of generic drug statute also uses the proce-
dure of requiring two signature lines on all prescriptions; how-
ever, these statutes are more permissive: one signature line
indicates that substitution is not allowed and the other that the
pharmacist may substitute. 3 Thus the pharmacist does not
have to Substitute the lower cost generic drug. Again, this type
R.I. GEN. LAWS § 5-19-38 (Supp. 1978); VT. STAT. ANN. tit. 18, § 4605 (a) (Supp. 1978);
Wis. STAT. ANN. § 450.077(3) (West Supp. 1978).
" See FLA. STAT. ANN. § 465.30(3)(a) (West Supp. 1978); KRS § 217.894 (1977);
VT. STAT. ANN. tit. 18, § 4605(b) (Supp. 1978).
" See, e.g., N.J. STAT. ANN. § 24:6E-7 (West Supp. 1978); N.Y. EDUC. LAW § 6816-
a (McKinney Supp. 1978); PA. STAT. ANN. tit. 35, § 960.3(A) (Purdon 1977); W. VA.
CODE § 30-5-12b(b) (Supp. 1978).
62 See, e.g., the Pennsylvania statute which states: "The bottom of every prescrip-
tion blank shall be imprinted with the words 'substitution permissible' and 'do not
substitute' and shall contain two signature lines for the physician or other authorized
prescriber's signature on the line immediately above the chosen option." PA. STAT.
ANN. tit. 35 § 960.3(A) (Purdon 1977).
" See, e.g., ARIz. REv. STAT. ANN. § 32-1963.01 (A) & (E) (Supp. 1978); Del. Code
Ann. tit. 24, § 2589 (b) & (c) (Supp. 1978); GA. CODE ANN. § 79A-408.2 (a) (Supp. 1978);
Mo. ANN. STAT. § 338.056 (Vernon Supp. 1979); S.D. CODIFIED LAWS § 36-11-46.1 and
-11-46.3 (Supp. 1978); TENN. CODE ANN. § 52-1223 (Supp. 1978); WASH REv. CODE §
69.41.120 (Supp. 1977).
Georgia also requires that the lowest priced equivalent be used when the prescrip-
tion is written generically. GA. CODE ANN. § 79A-408.2 (b) (Supp. 1978).
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of statute permits an unscrupulous pharmacist to choose the
higher price brand name drug and thus defeat the purpose of
the law: to lower drug costs to the consumer. However, states
having permissive substitution statutes apparently feel that
the competitive market provides sufficient incentive for phar-
macists to make use of lower price generic substitutes. 4 Indeed,
it may be preferable to leave the final decision regarding sub-
stitution to the pharmacist, who has had five years of training
in pharmacology and is probably in a better position to com-
pare the various forms of a drug than a physician with only a
limited amount of training in this field. 5 This type of statute
allows a pharmacist freedom to exercise professional judgment
while also providing an easy veto for the prescriber who feels
that no substitution should take place."
The largest group of state generic drug laws simply permits
substitution unless the prescriber indicates in some manner
that substitution is not allowed.67 Two signature lines are not
provided on the prescription form. This provides the pharma-
cist with a degree of choice regarding the substitution without
requiring the prescriber expressly to authorize substitution.
These statutes have the advantage of simplicity-if the prescri-
" This is, of course, assuming that the pharmacies in a particular area are truly
competitive. In a survey of Michigan pharmacists after the adoption of a generic drug
law in that state, 60% said they substituted frequently or whenever possible. Michigan
Pharmacists Now Substituting More, DRUG Topics 13 (Jan. 17, 1978).
One danger with relying on competition to encourage substitution is that a phar-
macist may substitute when unsure of the equivalency of the products in order to avoid
an unfavorable competitive position. See Note, Generic Drug Bill, 30 ARK. L. Ray. 376,
377 (1976).
" See Feldmann, supra note 19, at 377. Although pharmacists may have training
superior to that of physicians in the field of drugs, they still face problems in choosing
equivalent substitutes. See notes 92 and 93 and accompanying text infra for a discus-
sion of the difficulty in determining equivalent drugs.
1 Along similar lines is the Alaska statute which provides for prescription forms
that contain boxes labeled "Dispense as written" and "Substitution allowed" which
the prescriber is supposed to check. If the "Substitution allowed" box is checked then
the pharmacist may substitute, but if no indication is made or if the "Dispense as
written" box is checked then the pharmacist may not substitute. ALASKA STAT. §
08.80.295 (a)-(c) (Supp. 1978).
0 See, e.g., ARK. STAT. ANN. § 72-1047 (Supp. 1977); CAL. Bus. & PROF. CODE §
4047.6 (West Supp. 1978); COLO. Rav. STAT. § 12-22-118.5 (Supp. 1976); IowA CODE
ANN. § 155.37 (1)(a) (West Supp. 1978); MD. ANN. CODE art. 43, § 273A (b) & (c) (Supp.
1978); MONT. REv. CODEs ANN. § 66-1530 (Supp. 1977); NEB. REV. STAT. § 71-5403 (1)
(Supp. 1978); OHIO REv. CODE ANN. § 4729.38 (A) (Page Supp. 1978); OR. REv. STAT. §
689.835 (1) & (2) (1977); S.C. CODE § R 99-22 (b) (1976).
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ber writes an ordinary prescription then the druggist may sub-
stitute. One drawback, however, is that by not forcing physi-
cians to make a choice when signing the prescription, the phy-
sician may not really consider the advisability of substitution.
Thus, the decision as to whether to use a lower priced generic
drug may often be left solely to the pharmacist. Another draw-
back, mentioned earlier, results from the possibility that the
pharmacist may actually sell a higher priced drug even though
a lower priced one of equal quality is available.
Finally, two states, Massachusetts68 and New Hamp-
shire,"' have adopted a unique approach to generic drug laws.
These states prepare formularies" of interchangeable drugs.
Massachusetts requires the physician, when prescribing drugs
listed on the formulary, to include the generic name of the
drug,7" while New Hampshire requires the words "or its generic
equivalent drug listed in the New Hampshire drug formulary"
to be written on the prescription when the drug is listed on the
formulary. 2 Pharmacists may then substitute the equivalent
drug. This appears to put an unnecessary burden on the physi-
cian who must check all prescriptions against the formulary to
ensure compliance.73 This task could more easily and efficiently
be performed by the pharmacist who will probably check the
formulary anyway in the process of filling the prescription.
Another problem with these statutes is that they do not give
the physician the option of indicating when substitution should
not take place. Instead, the formulary is conclusive as to the
prescriber, but the pharmacist still has the option of using the
brand name of the generic drug. Therefore, these laws are man-
datory as to the physician but permissive as to the pharmacist.
2. Use of a Formulary
It has been suggested that there are three general patterns
of generic drug statutes. Such a statute either (1) "allows sub-
" MAss. ANN. LAws ch. 17, § 13 (Michie/Law. Co-op Supp. 1978) and ch. 112,
§12D (Michie/Law. Co-op 1975).
" N.H. REv. STAT. ANN. § 146:6-b & 11 (Supp. 1973).
For an explanation of a formulary see note 45 supra.
b' MAss. ANN. LAws ch. 112, § 12D (Michie/Law. Co-op 1975).
72 N.H. REv. STAT. ANN. § 146:6-b (Supp. 1973).
r Failure to comply with the New Hampshire generic drug law is a misdemeanor.
N.H. REv. STAT. ANN. § 146:18 (Supp. 1973).
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stitution only within a predetermined list of drugs or formu-
lary," (2) "allows substitution of any drug that is not specifi-
cally forbidden," or (3) "allows for substitution of any drug
without any reference to a formulary either positive or nega-
tive.""
The first pattern is what is referred to as a "positive" or
"equivalent" formulary. This means that a list of drugs has
been determined to be biologically or therapeutically equiva-
lent and may be substituted for one another.75 The determina-
tion of equivalency can be made by either a group of experts
in the drug field7l or by individual pharmacists. 77 Several
states78 and the District of Columbia7 have positive formular-
ies. These formularies represent an attempt to guarantee that
any drugs substituted are truly equivalent to those originally
prescribed. For this reason many of the states that have more
mandatory substitution requirements use the positive formu-
laries.10 In this way they can ensure that substitution is only
compelled for truly equivalent drugs.
The idea of having a panel of experts decide which drugs
are equivalent and only allowing substitution within their pre-
pared list presents practical problems.81 It requires a good deal
of testing to determine when two drugs are biologically or ther-
apeutically equivalent. This testing takes time so that develop-
7 Goldberg, supra note 26, at 64.
7 See notes 32-40 and accompanying text supra for a discussion of equivalence.
' These groups of experts, often called Formulary Boards, generally include phy-
sicians, pharmacists, and pharmacologists. See, e.g., D.C. CODE ANN. § 33-831 (Supp.
1978); N.J. STAT. ANN. § 24:6E-5 (West Supp. 1978).
" See, e.g., FLA. STAT. ANN. § 465.30 (5) (West Supp. 1978); OHio Rav. CODE ANN.
§ 4729.36 (H) (Page Supp. 1978).
71 See, e.g., Am. REv. STAT. ANN. § 32-1963.01 (B) (Supp. 1978); FLA. STAT. ANN.
§ 465.30 (6) (West Supp. 1978); K.R.S. § 217.819 (1977); MAss. ANN. LAws ch. 17, §
13 (Michie/Law. Co-op Supp. 1978); N.H. Rev. STAT. ANN. § 146:11 (Supp. 1973); N.J.
STAT. ANN. § 24:6E-6 (West Supp. 1978); N.Y. PuB. HmLTH LAw § 206 (McKinney
Supp. 1978); Omo Ray. CODE ANN. § 4729.36 (H) (Page Supp. 1977); PA. STAT. ANN.
tit. 35, § 960.5 (B) (Purdon 1977); R.I. GEN. LAws § 42-18.1-3 (Supp. 1978); TEN. CODE
ANN. § 52-1224 (Supp. 1978); VT. STAT. ANN. tit. 18, § 4601 (4) (Supp. 1978); VA. CODE
§ 54-524.109:14 (1978); Wis. STAT. ANN. § 140.90 (1)(d) (West Supp. 1978).
7, D.C.CoiDa ANN. § 33-831 (Supp. 1978).
" See, e.g., FLA. STAT. ANN. § 465.30 (West Supp. 1978); KRS §§ 217.19 & .822
(1977); N.J. STAT. ANN. §§ 24:6E-6 & 7 (West Supp. 1978); N.Y. EDUC. LAw § 6816-a
(McKinney Supp. 1978) & N.Y. PuB. HEALTH LAW § 206 (McKinney Supp. 1978); PA.
STAT. ANN. tit. 35, §§ 960.3 (A) & .5 (B) (Purdon.1977); VT. STAT. ANN. tit. 18, §§ 4601
(4) & 4605 (Supp. 1978); Wis. STAT. ANN. §§ 140.90 (1)(d) & 450.075 (West Supp. 1978).
N' See generally Note, supra note 15, at 407-08.
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ing a positive formulary is a slow process. This means that,
until an exhaustive list has been prepared, the number of drugs
that can be substituted is small. Even though the number may
increase over time, it is questionable whether such a formulary
could ever catch up with the more than 20,000 drug products
now available" and the new drugs that are added every year.
In addition to being slow, the process of developing a positive
formulary entails a great deal of expense. Therefore, it is lim-
ited by the amount of appropriations allocated by the legisla-
ture. Furthermore, limited funds may encourage formulary
boards to be less careful in determining equivalence. For all
of these reasons the benefits of a positive formulary may be
outweighed by the problems of developing such a list.s5
The second statutory pattern is the "negative" or "non-
equivalent" formulary which lists drugs that have been found
not to be or are suspected of not being biologically or thera-
peutically equivalent and provides that substitution of such
drugs is forbidden." The theory behind this type of law is
that most chemically equivalent drugs are also therapeutically
equivalent and that substitution should be freely allowed-un-
less there is some reason to suspect inequivalence s7 In this
way a measure of protection is provided without the expense
and delay a positive formulary would involve. The negative
"* See DRUG BIOEQUIVALENCE, supra note 20, at 21.
a The budget for the Kentucky Drug Formulary Council was $185,000 for fiscal
year 1978-79 and is $194,300 for fiscal year 1979-80. KENTUCKY EXEcUMvE BUDGET
1976/78.
For example, they may rely on information and testing done by manufacturers
rather than on their own testing.
" A study conducted by the federal government suggested one possible solution.
It was suggested that a distinction be drawn between drugs in which bioequivalency
is critical and those in which it is not so important. For those drugs where bioequiva-
lency is not essential, substitution would be permitted even though they had not been
determined equal and placed on the formulary. For those drugs in which bioequiva-
lency is essential substitution would not be allowed until they were placed on the
formulary. More drugs would be available for substitution sooner under this approach.
See DRUG BIOEQUIVALENCE, supra note 20, at 57. See also Note, supra note 23, at 904.
" See, e.g., ARK. STAT. ANN. § 72-1049 (Supp. 1977); CAL. Bus. & PROF. CODE §
4047.7 (West Supp. 1978); DEL. CODE ANN. tit. 24, § 2589 (d) (Supp. 1978); FLA. STAT.
ANN, § 465.30 (6) (West Supp. 1978); IOWA CODE ANN. § 155.36 (Supp. 1978); MD. ANN.
CODE art. 43, § 273A (e) (Supp. 1978); Mo. ANN. STAT. § 338.057 (Vernon Supp. 1979);
W. VA. CODE § 30-5-12b (h) & (i) (Supp. 1978).
11 As a government study concluded: "It is neither feasible nor desirable that
studies of bioavailability be conducted for all drugs or drug products." DRUG BOEQUI-
VALENCE, supra note 20, at 21.
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formulary represents a compromise between restricting sub-
stitution to the drugs on a positive formulary and providing
no guidelines at all for substitution."
The problem with using a negative formulary, however, is
that it does not protect against the previously undiscovered
inequivalency of two products that are generically the same.8'
Presumably, a positive formulary would discover any inequiva-
lencies before a drug is placed on the list and used as a substi-
tute." Thus, while a negative formulary may be easier to de-
velop, it may not provide as much protection for the consumer
as a positive formulary.
Some states" do not provide for a formulary, but allow
substitution based on the pharmacist's own professional judg-
ment. While it may be argued that the pharmacist is especially
trained in the drug field and should be able to make such
decisions, even the experts have a difficult time determining
therapeutic equivalency. 2 Thus the danger exists that non-
equivalent drugs will be substituted," or a pharmacist may be
overly cautious and refrain from substituting,'4 thereby defeat-
ing the purpose of the generic drug law.
Colorado and Nebraska have adopted novel approaches to
the problem of ensuring equivalency and developing a formu-
lary." These states do not have a state formulary but rather use
a list of drugs, prepared by the federal government, that are
suspected of not being biologically equivalent." This negative
0 Note, supra note 15, at 408.
0 A "positive" formulary gives the pharmacist and consumer more assurance of
the drugs' equivalency before substitution takes place. See Note, supra note 64, at 377.
" Whether or not non-equivalence is discovered depends on the extent of testing
done by a Formulary Board.
"1 See e.g., ALASKA STAT. § 08.80.295 (Supp. 1978); GA. CODE ANN. § 79A-408.2
(Supp. 1978); ME. REv. STAT. tit. 32, § 2806 (1978); MONT. Rav. CODEs ANN. § 66-1530
(Supp. 1977); OR. REV. STAT. § 689.835 (1977); S.C. CODE § R99-22 (1976); S.D. CODI-
FIED LAWS § 36-11-46.3 (Supp. 1978); WASH. RIV. CODE § 69.41.120 (Supp. 1977).
," See notes 37-38 and accompanying text supra for a discussion of this difficulty.
13 Pharmacists given a list of prescription drugs and asked to identify possible
substitutes for those drugs averaged only 57% correct. See Goldberg, supra note 26, at
69.
" See generally Myers and Fink, Liability Aspects of Drug Product Selection, 17
J. Am. PHARM. A. 33 (1977).
0 COLO. Rav. STAT. § 12-22-118.5 (1)(a) (Supp. 1976); NEB. REv. STAT. § 71-5402
(5) (Supp. 1978).
" This list is not a regular formulary but a list of "multiple-source drugs" for
which the government will only pay a set "maximum allowable cost" (MAC) when
1978-791
KENTUCKY LAW JOURNAL
formulary appears to be the optimal solution. Since drug bioe-
quivalence is a nation-wide problem it is more practical to have
a national list rather than have each state develop its own.
"Rather than patchwork state-by-state legislation, it would
seem incumbent on the federal government to measure up to
its public obligation and promulgate more stringent procedures
in order to prevent the marketing of inefficacious drugs.19 7 In
addition, this list provides the pharmacist with some guide-
lines in making substitution and the state is spared the expense
of developing a formulary.
3. Other Characteristics of Generic Drug Laws
While the permissibility of substitution and the type of
formulary are the basic variables of any generic drug law, all
such laws contain other provisions which are included to im-
prove the operation of the law. The nature of these additional
provisions varies greatly from state to state; however, there are
some fairly standard ones that are noteworthy.
To ensure that generic drug substitution laws actually de-
crease the cost of prescription drugs, many states provide that
a pharmacist may only substitute a lower cost generic equiva-
lent.'" In addition, there may be a provision requiring that the
cost savings resulting from the substitution be passed on to the
consumer" and that the pharmacist may not charge a higher
fee for dispensing a generic drug than for dispensing a brand
name drug. 1°0 Some states01 try to protect the consumer as to
reimbursing for prescriptions under Medicare and other government assistance pro-
grams. See 45 C.F.R. §§ 19.1 - .6 (1977).
In furtherance of the MAC program the federal government has developed proce-
dures for determining bioavailability and requires bioavailability data on certain
drugs. See 21 C.F.R. §§ 320.1 - .62 (1978).
" Note, supra note 23, at 904. It has been suggested that the Food and Drug
Administration may publish a positive formulary of interchangable drugs, probably as
an effort to enforce its MAC program. See Haddad, Generic Drugs-Tomorrow's
Market, 33 FOOD, DRUG, CONSM. L. J. 488, 490 (1978).
" See, e.g., ARK. STAT. ANN. § 72-1047 (Supp. 1977); CAL. Bus. & PROF. CODE §
4047.6 (c) (West Supp. 1978); VA. CODE § 54-524.109:12 (B) (1978).
" See, e.g., DEL. CODE ANN. tit. 24, § 2589 (b)(2) (Supp. 1978); OHIO REv. CODE
ANN. §14729.38 (2) (Page Supp. 1978); PA. STAT. ANN. tit. 35 § 960.3 (c) (Purdon 1977);
TENN. CODE AN. § 52-1223 (Supp. 1978); UTAH CODE ANN. § 58-17-31 (2) (Supp. 1977);
VA. CODE § 54-524.109: 12(b) (1978).
" See, e.g., CAL. Bus. & PROF. CODE § 4047.6 (c) (West Supp. 1978).
"7 See, e.g., ALASKA STAT. § 08.80.295 (g) (Supp. 1978); Aiuz. REv. STAT. ANN. §
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quality by providing conditions which a drug must meet before
it may be used as a substitute. These conditions require that
drug manufacturers provide adequate quality control and
stand behind their products.12
Another common provision in generic drug laws is the re-
quirement that the consumer be notified of the substitution.1 3
In addition, some states allow the consumer to refuse the sub-
stitution."' While it may seem like a good idea to allow the
consumer the freedom of choice, it may have some undesirable
side effects. Drug manufacturers are now advertising directly
to consumers," 5 suggesting that generic substitutes are not of
the same quality as brand name drugs."° To the extent manu-
facturers are successful in their effort to encourage consumers
to refuse generic drugs, the effectiveness of the generic drug
laws will be impaired."'
32-1961.01 (J) (Supp. 1978); NEB. R v. STAT. § 71-5403 (5) (Supp. 1978); S.D. CODnFIED
LAws § 36-11-46.4 (Supp. 1978); WASH. REV. CODE § 69.41.140 (Supp. 1977).
1,2 For example, one statute provides that certain manufacturing standards must
be met before a drug of the particular company may be used as a substitute. The
company must be one that: "(1) Marks capsules and tablets with identification code
or monogram; (2) Labels products with their expiration date; (3) Provides reasonable
services to accept return goods that have reached their expiration date; (4) Maintains
reasonable resources for product information; and (5) Maintains recall capabilities for
unsafe or defective drugs." S.D. CODIFED LAWS § 36-11-46.4 (Supp. 1978).
"I See, e.g., FLA. STAT. ANN. § 465.30 (3)(a) (West Supp. 1978); MONT. Rzv. CODES
ANN. § 66-1531 (1) (Supp. 1977); PA. STAT. ANN. tit. 35 § 960.3 (B) (Purdon 1977); UTAH
CODE ANN. § 58-17-31 (4) (Supp. 1977); VT. STAT. ANN. tit. 18, § 4605 (b)(Supp. 1978);
W. VA. CODE § 30-5-12b (j) (Supp. 1978); Wis. STAT. ANN. § 450.075 (2) (West Supp.
1978).
Some states even require signs informing customers that substitution may take
place. See, e.g., FLA. STAT. ANN. § 465.30 (9) (West Supp. 1978); MONT. Rzv. CODES
ANN. § 66-1531 (2) (Supp. 1977); NEB. REV. STAT. § 71-5403 (4) (Supp. 1978); OR. Rzv.
STAT. § 689.835 (3) (1977); PA. STAT. ANN. tit. 35, § 960.4 (Purdon 1977); WASH. REv.
CODE §'69.41.160 (Supp. 1977).
"I See, e.g., FLA. STAT. ANN. § 465.30 (3)(a) (West Supp. 1978); MONT. REv. CODES
ANN. § 66-1531 (1) (Supp. 1977); PA. STAT. ANN. tit. 35 § 960.3 (B) (Purdon 1977); VT.
STAT. ANN. tit. 18, § 4605 (b) (Supp. 1978).
10 This represents a shift from the former practice of advertising toward physi-
cians. See Willig, supra note 2, at 16.
I" One advertisement by the Pharmaceutical Manufacturers Association reads:
"Before you ask your pharmacist for a cheaper version of the medication prescribed
by your doctor, consider. In making the 'same' drug, different companies may exercise
different levels of skill and care. They formulate and manufacture the 'same' product
differently." Advertisement, SATURDAY REVIEW (Feb. 3, 1979).
,0 In fact manufacturers are conducting a campaikn for the passage of laws which
"would allow a consumer to specify a brand name in states where substitution is
permitted or mandated." Haddad, supra note 97, at 489.
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Finally, there are provisions which set a standard of care
for pharmacists or limit their potential liability when making
substitutions.' These provisions generally state that "[t]he
liability of a . . . [pharmacist] in substituting . . . shall be
no greater than that which is incurred in the filling of a generi-
cally written prescription." ' 9 Such provisions are included in
some generic drug laws because of fears of increased liability if
the druggist takes a more active role in selecting the drug prod-
uct to be dispensed,"0 and to avoid deterring pharmacists from
making substitutions."' While these provisions may help pro-
tect a pharmacist against claims of negligence, they do not
protect against other theories under which a pharmacist may
be held liable, such as strict products liability or breach of
implied warranty.' In order to provide full protection it might
be necessary to "enact a statutory exemption which would ab-
solve the pharmacist from liability caused by dispensing a ge-
neric substitute.""' However, it may not be desirable to lessen
any liability. Substitution will probably still take place be-
cause of the competitive advantage it provides, and potential
liability may make pharmacists more careful in selecting which
products to use as substitutes."4
" See, e.g., ARiz. REV. STAT. ANN. § 32-1963.01.(H) (Supp. 1978); FLA. STAT. ANN.
§ 465.30 (10) (West Supp. 1978); PA. STAT. ANN. tit. 35, § 960.6 (Purdon 1977); R.I.
GEN. LAws § 42-18.1-5 (Supp. 1977).
I" Amuz. REV. STAT. ANN. § 32-1963.01 (H) (Supp. 1978).
As to the general standard of care for a pharmacist: "A druggist is not an absolute
insurer; it is his duty to act with due, ordinary care and diligence in selling and
dispensing drugs, that is, such care as is ordinarily possessed and exercised by mem-
bers of his profession." Annot., 79 A.L.R.2d 301, 315-16 (1961).
"I See generally Myers and Fink, supra note 94, at 33.
The increased liability may come from substituting drugs that are chemically
equivalent but not therapeutically equivalent. These fears of liability are directed
mainly at the pharmacist who is given the choice of substitution. Presumably where
substitution is mandated by statute from a "positive" formulary the pharmacist could
not be held liable if the substitution was made according to proper procedures.
"I See generally Note, supra note 23, at 897.
This danger may be more imagined than real since "[tihus far, no known re-
ported cases have been found in which a pharmacist has been held liable for inappro-
priate prescription product sources selection [substitution]." Myers and Fink, supra
note 94, at 33.
M2 See generally Myers and Fink, supra note 94; Note, supra note 65.
" Note, supra note 23, at 897.
"' This is particularly important in those states that allow substitution but pro-
vide no formulary for pharmacists to use as a guide.
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B. The Experience in Kentucky
In 1966 the Kentucky Board of Pharmacy, pursuant to its
powers to regulate the pharmacy profession, issued a regulation
forbidding substitution of drugs without the consent of the
prescriber.' However, in 1972 the legislature overrode this an-
tisubstitution regulation by enacting Kentucky's first generic
drug law. "6 This law provided for the creation of a drug formu-
lary council "1 7 which was given the duty of preparing a formu-
lary of therapeutically equivalent drugs (i.e., a "positive" for-
mulary)."' When there were equivalent drugs listed in the for-
mulary a pharmacist was permitted to substitute, and was
required to do so if the consumer requested it."' The Kentucky
law was fairly permissive even though the number of instances
in which the pharmacist had the option of substitution was
limited to those where the drug was listed in the formulary.',
It was unlikely that any consumer would request substitution
since the pharmacist was not required to inform the consumer
of this option. Thus the pharmacist retained a great deal of
control.
Then in 1976, in order to further the avowed legislative
intent "that all citizens of Kentucky may be assured of high
quality medicine at a reasonable cost,"1'' the generic drug law
was revised. The law was strengthened by providing that a
pharmacist "shall select the lowest priced therapeutically
"5 4 KY. AD. REGS., Pharmacy Rx-8 (1974).
"' 1972 Ky. Acrs, ch. 126, §§ 1-13.
1972 Ky. AcTs, ch. 126, § 5.
"' Id. at § 6.
"' Id. at § 8.
' At first there was some question as to whether a pharmacist could substitute
even if the drug was not on the formulary since there was no prohibition against such
substitution. The Board of Pharmacy cleared up this question by issuing a regulation
stating:
Except as provided elsewhere by statute, whenever any registered phar-
macist is requested to sell, furnish, or compound any drug, medicine, chemi-
cal, or pharmaceutical preparation by means of a prescription and substi-
tutes or causes to be substituted therefor, any other drug, medicine, chemi-
cal, or pharmaceutical preparation without specific or express permission,
approval or consent of the prescriber, the board may find such person guilty
of engaging in dishonorable, unethical, or unprofessional conduct of a char-
acter likely to deceive, defraud, or harm the public, and may revoke or
suspend his license as prescribed by law.
201 Ky. AD. RFas. 2:080 (1978).
121 KRS § 217.825 (1977).
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equivalent drug listed by the drug formulary council which he
has in stock, unless otherwise instructed by the purchaser or his
physician." ' While it may seem that this mandatory substitu-
tion would ensure that the consumer receives prescription
drugs at the lowest possible price, in actuality it is fairly easy
to avoid the mandate of this law. This is done by limiting the
drugs which are kept in stock since the statute says substitu-
tion only has to be made with the lowest equivalent drug in
stock." Therefore, in practice the Kentucky pharmacist has
some control just like pharmacists in states with more
"permissive" generic drug laws.124 Thus, the extent of substitu-
tion still depends in part on the amount of competition in the
prescription drug field.
The 1976 generic drug act also added some totally new
provisions to the law. One was the requirement of a sign in
every pharmacy advising consumers of the existence of and
their rights under the generic drug law.12 But it appears that
this sign has not been very effective. A 1977 survey of adult
Kentuckians conducted for the Kentucky Drug Formulary
Council showed that "31.5% knew about the Generic Drug
Law; 19.3% had noticed a sign in their pharmacy; 7.8% had
discussed the law with either their doctor or pharmacist."126
Another new provision states that "[t]he substitution of any
drug by a pharmacist. . . does not constitute the practice of
medicine. 127 The Office of the Attorney General interprets this
as meaning that "a pharmacist incurs no liability for substitu-
tion so long as it was done pursuant to the law and not the
I= KRS § 217.822 (1977) (emphasis added). Of course, there is still the problem
that, according to the wording of the current statute, when a prescription is written
generically the lowest priced generic drug does not have to be used. See notes 52-58
and accompanying text supra for a discussion of this problem.
I- KRS § 217.822 (1977).
212 The difference is that a Kentucky pharmacist cannot decide about substitution
in individual cases but can only decide generally by not stocking some or all of the
generic forms of a particular drug.
This choice may not be such a bad thing. One commentator has said that pharma-
cists should not be required to dispense the lowest cost drug against their professional
judgment because the individual pharmacist may be aware of specific product defects.
See Cabana, Bioavailability/Bioequivalence, 32 FooD, DRUG, CosM. L. J. 512, 526
(1977).
,, KRS § 217.894 (1977).
22 Minutes of Kentucky Drug Formulary Council meeting (Dec. 13, 1977).
2 KRS § 217.822 (3) (1977).
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result of negligence on the part of the pharmacist."1 8
Kentucky has made a good faith effort to see to it that
consumers receive quality drugs at the lowest cost. And even
though there are still problems with the generic drug law, rqvi-
sions have been made to solve some of them. It is still unclear
what effect this law has actually had. The Attorney General's
Office says they have found "no evidence of widespread viola-
tions of the law."' However, a survey conducted by a Ken-
tucky newspaper discovered that while most pharmacies fol-
lowed the law and substituted a generic drug, there were still
large variations in price.11 Therefore, the question must be
asked: What else could be done to better protect the consumer?
C. Solutions Other Than Generic Drug Laws
Solutions other than generic drug laws have been sug-
gested to aid the consumer in the area of prescription drugs.
Much of the early impetus in the consumer protection move-
ment came in the area of prescription drug price advertising.
Such advertising, which is constitutionally protected,1 ' is now
provided for by statute in some states.' Advertising is an aid
to the consumer in that it facilitates comparison shopping,
which is difficult to do in the prescription drug field where the
products are not accessible to the consumer. To encourage this
further, some states have made price posting for certain pre-
scription drugs mandatory."'
lu Letter from H. Regina Cullen, Assistant Attorney General for the Common-
wealth of Kentucky (March 1, 1978).
See also Willig, supra note 2, at 30-31 for a discussion of the liability problem
under the 1972 Act.
I" Letter from H. Regina Cullen, Assistant Attorney General for the Common-
wealth of Kentucky (March 1, 1978).
Each violation of the generic drug law results in a fine of not less than $100 and
not more than $500. KRS § 217.990 (10) (1977).
"' Anderson, Local Pharmacies Selling Generic Drugs, But Prices Vary Widely,
Lexington Herald-Leader, Jan. 21, 1979, at 1, col. 1.
1I See Virginia State Board of Pharmacy v. Virginia Citizens Consumer Council,
Inc., 425 U.S. 748 (1976). See also Comment, A Step Forward for the Consumer: A
Constitutional Right-to-Know in Prescription Drug Price Advertising, 13 URn. L. ANN.
179 (1977).
-22 See, e.g., ARK. STAT. ANN. § 72-1051 (Supp. 1977); CAL. Bus. & PoR. CODE §
4047.8 (West Supp. 1978); CLO. Rzv. STAT. § 12-22-123.5 (Supp. 1976); S.D. CODIFTED
LAws § 36-11-47.1 (Supp. 1978).
113 See, e.g., D.C. CODE ANN. § 33-813 (Supp. 1978); ME. Rav. STAT. tit. 22, § 2204-
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One ingenious proposal is to abolish or limit the trademark
protection of brand name drugs. 34 Thus, all drugs would be
sold under their generic names and thus even under antisubsti-
tution laws substitution would occur. The problem with this
proposal is that without additional legislation this would not
guarantee that the consumer would get the lowest cost product
available. In addition, the drug manufacturers are moving to-
ward "branded generics," which is an attempt to have the
consumer request a particular manufacturer's product even
though it is sold under a generic name. 35
CONCLUSION
In the final analysis, generic drug substitution laws are
probably the best way of protecting the consumer. Admittedly,
these laws have certain drawbacks, but many of the problems
can be alleviated through statutory revision. Below is a sug-
gested model statute that attempts to correct some of these
problems by incorporating the best provisions of various state
statutes and making changes where necessary.
Model Generic Drug Substitution Act
§ 1 Policy-It is declared to be the public policy of this
state that all citizens receive high quality medicine at a reason-
able cost.
§ 2 Definitions-As used in this act:
(a) "Brand name" shall mean the proprietary or trade
name given to a drug product by its manufacturer or distribu-
tor;
(b) "Generic name" shall mean the official name, as de-
termined by the United States Adopted Names as published by
the United States pharmacopeal convention and accepted by
the federal Food and Drug Administration, of those drug prod-
ucts having exactly the same active chemical ingredients in
exactly the same strength and quantity;
(c) "Therapeutically equivalent" shall mean those drugs
containing the identical active ingredients in exactly the same
F (1975); N.Y. EDuc. LAw § 6826 (McKinney Supp. 1978); W. VA. CODE § 30-5-12a
(1976),
'1' See 1977 Legislative Outlook, AM. DRUGGIST 16 (Jan. 1977).
"I Haddad, supra note 97, at 489.
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strength, quantity, and dosage form and of the same generic
name, which, when administered in the same amounts will
provide the same therapeutic effect as evidenced by the control
of a symptom or disease;
(d) "Bioequivalent" shall mean those drugs containing
the identical active ingredients in exactly the same strength,
quantity and dosage form and of the same generic name,
which, when administered in the same amounts, will provide
essentially the same biological or physiological availability as
measured by blood levels or other appropriate methods;
(e) "Drug" shall mean any chemical human medication
with one or more known active ingredients;
(f) "Substitute" shall mean to dispense without the pres-
criber's express authorization a different drug product in place
of the drug product prescribed;
(g) "Prescriber" shall mean any practitioner licensed by
this state to write prescriptions for drugs, medications, or de-
vices;
(h) "Pharmacist" shall mean any person licensed as
such by the state board of pharmacy.
§ 3 Substitution of lowest priced equivalent drugs-
(a) Whenever a pharmacist receives a prescription for a
brand name drug, the pharmacist shall substitute the lowest
priced drug of the same generic name which in the pharma-
cist's reasonable professional judgment is therapeutically
equivalent, unless otherwise instructed by the purchaser or
prescriber.'
(b) Whenever a pharmacist receives a prescription for a
generic name drug, the pharmacist shall dispense the lowest
priced drug of that generic name which in the pharmacist's
reasonable professional judgment is therapeutically equiva-
lent."'3
(c) If the lowest priced drug of the same generic name
I The act uses the word "shall" so as to make the substitution mandatory.
However, the pharmacist is allowed some choice in determining which drugs are thera-
peutically equivalent. This is an attempt to avoid relying entirely on competition to
guarantee substitution (as do the permissive statutes) while permitting the pharmacist
to exercise professional judgment in determining which drugs are equivalent and ap-
propriate as substitutes.
"I This section is included to ensure that prescriptions written generically are also
filled with the lowest priced equivalent drug. See notes 52-58 and accompanying text
supra for a discussion of this problem.
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which in the pharmacist's reasonable professional judgment is
therapeutically equivalent to the drug prescribed is not avail-
able in stock the pharmacist shall so inform the purchaser. The
pharmacist may then substitute the lowest priced drug of the
same generic name which in the pharmacist's reasonable pro-
fessional judgment is therapeutically equivalent to the drug
prescribed and which is available in stock, if the purchaser so
consents.'
§ 4 When substitution prohibited-
(a) No substitution shall be made with any drug product
which has been found to be therapeutically inequivalent by the
federal Food and Drug Administration, or which is listed as
having a known or potential bioequivalence problem by the
federal Department of Health, Education, and Welfare.'
(b) The state board of pharmacy shall be required to
publish and distribute such list of drugs determined to be ther-
apeutically inequivalent or having known or potential bioequi-
valence problems.
(c) No substitution shall be made with a drug unless the
manufacturer of that drug has shown that:
(1) All products submitted have an expiration date on
the original package;
(2) The manufacturer maintains recall and return cap-
abilities for unsafe or defective drugs:
(3) The manufacturer maintains quality control stan-
dards equal to those of the federal Food and Drug Adminis-
tration.
§ 5 Price savings passed on to consumer-All differences
in price between the drug prescribed and the drug dispensed
shall be passed on to the consumer. In no event may the phar-
macist charge a different professional fee for dispensing a dif-
ferent drug product than the drug product originally pre-
scribed.
13 This provisibn is to encourage pharmacists to keep the lowest priced generic
equivalent drugs in stock so as to avoid having to get the purchaser's consent before
the next lowest priced equivalent can be used for the substitute. This method was
chosen rather than requiring pharmacies to stock the lowest priced generic equivalents
because of the difficulties of enforcing such a requirement. Pharmacies must rely on
their wholesale suppliers for drugs and may not always be able to get certain drugs.
"I This section is designed to provide some guidelines for the pharmacist in deter-
mining equivalent drugs with which to substitute without requiring the expense of
preparation of a formulary.
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§ 6 Records and labeling-
(a) When a drug is substituted the pharmacist shall re-
cord on the prescription form the name and manufacturer of
the drug substituted, and shall retain the form for inspection.
(b) When a drug is substituted the pharmacist shall label
the medication container with the name of the drug substi-
tuted.
§ 7 Sign required notifying the public-Every pharmacy
shall post a sign in a location easily seen by patrons at the
counter where prescription drugs are dispensed stating, in
block letters of not less than one inch in height, that "This
pharmacy is required to dispense the lowest priced generic drug
which is therapeutically equivalent to the one prescribed for
you by your doctor unless you or your doctor do not approve."
§ 8 Posting of prices permitted-A pharmacist may dis-
play, within the confines of the pharmacy, lists of available
drug products and current charges for the drug products in
specified quantities.
§ 9 Liability of pharmacist-
(a) A pharmacist in making a substitution shall assume
the same responsibility for selecting the dispensed drug prod-
uct as would be incurred in filling a prescription for a generic
name product.
(b) Substitution of drugs in accordance with this act
shall not constitute evidence of negligence or improper phar-
macy practice if the substitution was made within reasonable
and prudent pharmacy practice or if the prescribed and substi-
tuted drugs were therapeutically equivalent.
(c) The substitution of any drug by a pharmacist under
this act does not constitute the practice of medicine.
§ 10 Liability of prescriber-The failure of a prescriber
to specify that no substitution is authorized does not constitute
evidence of negligence.
§ 11 Enforcement and penalities-
(a) Failure to comply with the provisions of this act shall
be a tortious injury and any person failing to comply shall be
liable for treble civil damages to every person, including insur-
ers and government agencies, injured thereby. 40
"I Since it is often difficult for the state to investigate and enforce compliance
with generic drug laws, this provision for treble civil damages is to encourage consum-
ers to take some initiative in policing these laws.
1978-79]
414 KENTUCKY LAW JOURNAL [Vol. 67
(b) A pharmacist who violates a provision of this act
shall be subject to a fine of not more than $500 for each occur-
ance, and shall be subject to discipline by the state board of
pharmacy, including but not limited to suspension or revoca-
tion of license.'
Jillena A. Warner
'" The author wishes to thank Ben H. Doyle and Joe C. McMurtry, registered
pharmacists, for their assistance.
